Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Matthew D Aldridge"'
Autor:
Javian C. Malcolm, Nadia Falzone, Jennifer E. Gains, Matthew D. Aldridge, David Mirando, Boon Q. Lee, Mark N. Gaze, Katherine A. Vallis
Publikováno v:
EJNMMI Physics, Vol 9, Iss 1, Pp 1-14 (2022)
Abstract Purpose Recent reports personalizing the administered activity (AA) of each cycle of peptide receptor radionuclide therapy based on the predicted absorbed dose (AD) to the kidneys (dose-limiting organ) have been promising. Assuming identical
Externí odkaz:
https://doaj.org/article/a7f8eaf089e44f72a76a7b42c9598055
Autor:
Charlotte Atkinson, Balaji Ganeshan, Raymond Endozo, Simon Wan, Matthew D. Aldridge, Ashley M. Groves, Jamshed B. Bomanji, Mark N. Gaze
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
PurposeNeuroendocrine tumors (NET) are rare cancers with variable behavior. A better understanding of prognosis would aid individualized management. The aim of this hypothesis-generating pilot study was to investigate the prognostic potential of tumo
Externí odkaz:
https://doaj.org/article/bd9552698d954fc3ba77a020059f7bc2
Autor:
Veronica Moroz, Connie Peet, Keith Wheatley, Matthew D Aldridge, Jamshed Bomanji, Jennifer Laidler, Mark N. Gaze, Jennifer E. Gains, Simon Wan
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 47:2348-2357
The objective of this phase IIa, open-label, single-centre, single-arm, two-stage clinical trial was to evaluate the safety and activity of 177-lutetium DOTATATE (LuDO) molecular radiotherapy in neuroblastoma. Children with relapsed or refractory met
Autor:
Jill Tipping, April-Louise Smith, James Scuffam, Bruno Rojas, Allison J. Craig, Matthew D Aldridge, Daniel R. McGowan, Jonathan Gear, Catherine J Scott
Publikováno v:
The British journal of radiology. 94(1126)
The Internal Dosimetry User Group (IDUG) is an independent, non-profit group of medical professionals dedicated to the promotion of dosimetry in molecular radiotherapy ( www.IDUG.org.uk ). The Ionising Radiation (Medical Exposure) Regulations 2017, I
Autor:
Balaji Ganeshan, Jamshed Bomanji, Raymond Endozo, Matthew D Aldridge, Ashley M. Groves, Charlotte Atkinson, Simon Wan, Mark N. Gaze
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
PurposeNeuroendocrine tumors (NET) are rare cancers with variable behavior. A better understanding of prognosis would aid individualized management. The aim of this hypothesis-generating pilot study was to investigate the prognostic potential of tumo
Autor:
Javian C, Malcolm, Nadia, Falzone, Jennifer E, Gains, Matthew D, Aldridge, David, Mirando, Boon Q, Lee, Mark N, Gaze, Katherine A, Vallis
Publikováno v:
EJNMMI physics. 9(1)
Recent reports personalizing the administered activity (AA) of each cycle of peptide receptor radionuclide therapy based on the predicted absorbed dose (AD) to the kidneys (dose-limiting organ) have been promising. Assuming identical renal pharmacoki
Autor:
Matthew D Aldridge, Connie Peet, Jamshed Bomanji, Simon Wan, Mark N. Gaze, LauraMay Davis, April-Louise Smith, Jack Foulkes, Jennifer E. Gains
Publikováno v:
Journal of Personalized Medicine
Journal of Personalized Medicine, Vol 10, Iss 174, p 174 (2020)
Journal of Personalized Medicine, Vol 10, Iss 174, p 174 (2020)
Molecular radiotherapy, or targeted radionuclide therapy, uses systemically administered drugs bearing a suitable radioactive isotope, typically a beta emitter. These are delivered via metabolic or other physiological pathways to cancer cells in grea
Autor:
Ananth Shankar, Jennifer E. Gains, Jamshed Bomanji, Matthew D Aldridge, Lorenzo Biassoni, Mark N. Gaze, Maria Vittoria Mattoli
Publikováno v:
Nuclear medicine communications. 41(11)
Purpose Iodine-131-labelled meta-iodobenzylguanidine (I-mIBG) and lutetium-177-labelled DOTATATE (Lu-DOTATATE) are used for molecular radiotherapy of metastatic neuroblastoma. These are taken up by the noradrenaline transporter (NAT) and the somatost
Autor:
Connie Peet, Jamshed Bomanji, Ananth Shankar, Mark N. Gaze, Simon Wan, Matthew D Aldridge, Jennifer E. Gains
Publikováno v:
Clinical oncology (Royal College of Radiologists (Great Britain)). 33(2)
The common contemporary indications for paediatric molecular radiotherapy (pMRT) are differentiated thyroid cancer and neuroblastoma. It may also have value in neuroendocrine cancers, and it is being investigated in clinical trials for other diseases
Publikováno v:
Br J Radiol
It has been almost a decade since the commentary Molecular radiotherapy — the radionuclide raffle? by Gaze and Flux (2010). The overarching feeling then was that no individual or organisation has taken up the challenge, nationally or internationall